South Korea's KRIBB, PuriosaAI sign MOU for AI-driven drug discovery
Korea’s KRIBB National Center for Preclinical Trials (KPEC) announced on the 13th that it signed a memorandum of understanding with PuriosaAI to establish an AI-driven drug development collaboration. The agreement was inked at PuriosaAI’s headquarters in Seoul and brought together representatives from Yonsei University College of Pharmacy, Omallos Korea, InsilicoX, and the Digital AI Cell Sejong Daewang Project Consortium, alongside KPEC officials.
The partners plan to integrate PuriosaAI’s second-generation neural processing unit, RNGD (Renegade), into bio research environments to run high-performance AI computations. They will center efforts on digital AI cells (virtual cells) and a digital bio platform to accelerate AI-assisted drug discovery, a process that relies on large-scale data analysis, model training and fast inference.
Participating institutions will collaborate across several areas, including AI-based drug discovery, the advancement of digital AI cells and digital bio platforms, development of bio-specialized language models and data analysis tools, and next-generation biotech-specific computational logic. They also aim to link data analytics platforms with computing farms to support scalable research.
PuriosaAI chief executive Baek Joon-ho said the convergence of AI semiconductors and biotech research is rapidly changing the drug discovery landscape. He stated that leveraging their NPU technology could accelerate AI-driven drug discovery and contribute to building the next generation of AI computing infrastructure for the digital-bio era.
KRIBB’s KPEC center director Ko Kyung-cheol described the MOU as an important starting point for connecting domestically produced NPU-based high-performance computing with frontline bio research. He said the collaboration would lead AI-based drug discovery innovation, advance the digital AI cell and digital bio platform ecosystem, and expand cooperation toward biotech-specific AI semiconductors, strengthening the AI digital-bio ecosystem in Korea.
Why this matters for the United States and global audiences - AI-enabled drug discovery is a strategic priority in both the United States and Korea, with cross-border potential for faster development of therapies and new biotech business models. The joint effort highlights Korea’s push to build domestic AI hardware and software platforms that can shorten development timelines for medicines. - The project signals possible shifts in the biotech supply chain, pairing Korean AI hardware with bio-research capabilities, which could diversify global partnerships for pharmaceutical innovation and reduce reliance on Western compute ecosystems alone. - U.S. readers should watch for potential collaboration opportunities with Korean research networks and tech firms that are integrating advanced AI accelerators into biotech pipelines, including virtual cell modeling and digital-twin approaches that are increasingly used in preclinical research and regulatory discussions.